Highlights from Fall Clinical Dermatology Conference 2025
Overcoming Treatment Inertia to Improve Outcomes in Atopic Dermatitis
In the era of targeted therapies, practitioners have a myriad of new tools at their disposal, which enable them to raise the standards of care for patients with atopic dermatitis (AD). The modern management of AD involves navigating this complex therapeutic landscape and identifying the treatments that can deliver the goals that are most relevant to individual patients. During this year’s Fall Clinical Dermatology Conference, in Las Vegas, Nevada, a panel of experts reviewed recommendations and outlined strategies for counseling patients with moderate-to-severe AD about treatment options that can improve treatment response and outcomes in this population.
October 27, 2025
Read moreDelgocitinib Cream Delivers Meaningful, Long-Term Symptom Improvement in Patients with Chronic Hand Eczema
Nearly half of patients treated with delgocitinib cream for 16 weeks achieved significant improvements in symptoms of chronic hand eczema (CHE) and quality of life, and nearly a third of those enrolled in the extension trial maintained the improvements 8 weeks after stopping treatment, according to data presented at the 2025 Fall Clinical Dermatology Conference in Las Vegas, Nevada.
October 28, 2025
Read moreRelated Articles
New Topical and Systemic Therapies Are Shifting the Paradigm for the Management of Chronic Hand Eczema
Emerging therapies are changing the way dermatologists think about the management of chronic hand eczema (CHE), while providing them with more options that can help achieve stable, long-term control of the disease. While CHE management traditionally centered on control of symptoms and flares, the development of novel agents that target the underlying mechanisms of CHE may provide durable improvements in symptoms and quality of life.
October 27, 2025
Read moreEffective Long-Term Management Is an Unmet Need for Patients with Chronic Hand Eczema
The toolbox for the treatment of chronic hand eczema (CHE) has continued to expand, with targeted therapies setting new standards for disease control. Nevertheless, findings from a survey of healthcare providers, presented at the 2025 Fall Clinical Conference in Las Vegas, revealed that many patients with moderate-to-severe CHE continue to struggle with inadequate management of their disease.
October 27, 2025
Read moreTralokinumab Passes Real-World Test in the Treatment of Moderate-to-Severe Atopic Dermatitis
Tralokinumab improved quality of life outcomes related to itch, sleep, and treatment satisfaction for individuals with moderate-to-severe atopic dermatitis (AD) followed for 52 weeks in a real-world study, regardless of prior dupilumab use. The final analysis of the prospective longitudinal study enrolling U.S.-based patients with AD from the Adbry® AdvocateTM Program was presented in a poster session at the 2025 Fall Clinical Dermatology Conference, in Las Vegas.
October 27, 2025
Read moreFrom Hands to Pockets: the High Cost of Managing Chronic Hand Eczema
The financial burden related to the costs of managing chronic hand eczema (CHE), which is often underestimated, represents a source of psychological distress and may be a barrier to care for individuals living with this skin disease. Findings from a study presented at the 2025 Fall Clinical Dermatology Conference in Las Vegas, Nevada showed that living with CHE translates into significant economic strain due to high healthcare resource utilization and out-of-pocket costs.
October 28, 2025
Read moreLong-Term Data Reinforce Safety of Upadacitinib in Treating Atopic Dermatitis in Oral Contraceptive Users
Women with atopic dermatitis (AD) who take oral contraceptive pills (OCPs) need not write off upadacitinib as a treatment option, according to pooled data from several phase 3 randomized clinical trials, which revealed a favorable benefit–risk profile of the Janus kinase (JAK) inhibitor in this population.
October 28, 2025
Read moreSocial Determinants of Health Shape the Course of Chronic Hand Eczema
Sociodemographic factors and comorbidities may influence the course and severity of chronic hand eczema (CHE), according to findings from the CHECK study of U.S.-based adults with CHE presented during a poster session at the 2025 Fall Clinical Dermatology Conference in Las Vegas. Understanding individual variations can guide treatment and prevention strategies and may ultimately minimize gaps in care for people with CHE.
October 28, 2025
Read more
© 2025 Wolters Kluwer. All right reserved.